Hims & Hers Health Inc HIMS shares are rising on Wednesday after BofA Securities and Canaccord Genuity raised their ...

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced Hims & Hers Benefits, a new way for subscribers to access the best ...

(Corrects paragraph 15 to reflect that Hims & Hers is one of the most volume-producing of Novo’s partners, and not the most ...

The company is profitable, and its subscriber base is growing. Hims & Hers makes and sells drugs. That's not remotely unusual. The key difference is the way the company interacts with its customers, ...

Hims & Hers Health delivered strong FY25 results with 59% revenue growth to $2.35B and 13% subscriber growth, but faces near-term margin pressure. Management guided FY26 revenue of $2.7–$2.9B and ...

Hims & Hers Health, Inc. is facing existential risk as regulatory uncertainty and margin erosion undermine its growth narrative. HIMS' reliance on compounded GLP-1 drugs has faltered, with regulatory ...

In recent days, Hims & Hers Health, Inc. amended its revolving credit agreement to support the completed acquisition of Australian telehealth company Eucalyptus and appointed longevity-focused ...

Hims & Hers Health expanded its Hims & Hers Benefits program with eight new partners, adding subscriber-only perks across fitness, nutrition, women's health, metabolic monitoring, and AI-powered ...

Hims had 2.6 million subscribers in Q1, up 9% year over year, with Q2 expected to show how much the Novo deal is helping ...

Hims & Hers Health announced it will sell Ozempic lookalike pills for $49 a month last week. The FDA objected Friday, and Novo Nordisk sued for patent infringement this morning. Where to invest $1,000 ...